Companies › Caribou Biosciences
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| CB-010 CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy | CD19 | Phase 1 | Lymphoma, Non-Hodgkin | Dec 2026 |
| Lornoxicam (CB-011) Cyclooxygenase inhibitor | PTGS2, PTGS1 | Phase 1 | Relapsed/Refractory Multiple Myeloma | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04637763 | CB-010 | Phase 1 | Lymphoma, Non-Hodgkin | Oncology | Dec 2026 |
| NCT05722418 | Lornoxicam (CB-011) | Phase 1 | Relapsed/Refractory Multiple Myeloma | Oncology | Dec 2027 |
Cash and short-term investments of $95m on 2026-09-30; operating cash outflow about $97m a year; runway about 12 months at that burn, to Sep 2027
Press releases filed as 8-K in the last year:
Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.